

| Study | Events | Total | Proportion | 95%-CI |
|-----------------------------|--------|-------------|--------------|-----------------------|
| industry = 1 | | | | |
| Tolcher2011Phase | 6 | 53 | 0.113 | [0.043; 0.230] |
| Bianchi2009Phase | 3 | 54 | 0.056 | [0.012; 0.154] |
| Awada2005Phase | 5 | 44 | 0.114 | [0.038; 0.246] |
| Bengala2010Sorafenib | 7 | 46 | 0.152 | [0.063; 0.289] |
| Flaherty2011Interaction | 4 | 21 | 0.190 | [0.054; 0.419] |
| Furuse2008Phase | 17 | 27 | 0.630 | [0.424; 0.806] |
| Clark2005Safety | 4 | 19 | 0.211 | [0.061; 0.456] |
| Hoftijzer2009Beneficial | 7 | 31 | 0.226 | [0.096; 0.411] |
| Akaza2007Phase | 41 | 131 | 0.313 | [0.235; 0.400] |
| Abou2006Phase | 14 | 137 | 0.102 | [0.057; 0.166] |
| Blumenschein2009Phase | 5 | 52 | 0.096 | [0.032; 0.210] |
| Elser2007Phase | 5 | 27 | 0.185 | [0.063; 0.381] |
| Ratain2006Phase | 71 | 202 | 0.351 | [0.286; 0.422] |
| Strumberg2005Phase | 6 | 69 | 0.087 | [0.033; 0.180] |
| Cheng2009Efficacy | 16 | 149 | 0.107 | [0.063; 0.169] |
| Escudier2007Sorafenib | 27 | 451 | 0.060 | [0.040; 0.086] |
| Llovet2008Sorafenib | 24 | 297 | 0.081 | [0.052; 0.118] |
| Dingemans2013Phase | 4 | 57 | 0.070 | [0.019; 0.170] |
| Pressiani2013Sorafenib | 44 | 297 | 0.148 | [0.110; 0.194] |
| Santoro2013Phase | 7 | 100 | 0.070 | [0.029; 0.139] |
| Brose2014Sorafenib | 43 | 207 | 0.208 | [0.155; 0.269] |
| Random effects model | | 2471 | 0.147 | [0.106; 0.199] |

Heterogeneity: I-squared=88.6%, tau-squared=0.6065, p<0.0001

| | | | | |
|-----------------------------|----|-------------|--------------|-----------------------|
| industry = 0 | | | | |
| Kelly2011Evaluation | 6 | 37 | 0.162 | [0.062; 0.320] |
| Jonasch2010Upfront | 10 | 40 | 0.250 | [0.127; 0.412] |
| Chi2007Phase | 2 | 28 | 0.071 | [0.009; 0.235] |
| Moore2005Phase | 4 | 41 | 0.098 | [0.027; 0.231] |
| Eisen2006Sorafenib | 5 | 37 | 0.135 | [0.045; 0.288] |
| Steinbild2007Clinical | 3 | 55 | 0.055 | [0.011; 0.151] |
| Dreicer2009Phase | 5 | 27 | 0.185 | [0.063; 0.381] |
| Dy2010Front | 5 | 25 | 0.200 | [0.068; 0.407] |
| Von2012Phase | 6 | 37 | 0.162 | [0.062; 0.320] |
| Yau2009Phase | 10 | 51 | 0.196 | [0.098; 0.331] |
| Minami2008Phase | 7 | 31 | 0.226 | [0.096; 0.411] |
| Dahut2008Phase | 2 | 22 | 0.091 | [0.011; 0.292] |
| Ahmed2011Analysis | 15 | 34 | 0.441 | [0.272; 0.621] |
| Bodnar2011Sorafenib | 1 | 11 | 0.091 | [0.002; 0.413] |
| Nimeiri2010Phase | 7 | 56 | 0.125 | [0.052; 0.241] |
| Borthakur2011Phase | 19 | 50 | 0.380 | [0.247; 0.528] |
| EI2012Randomized | 1 | 15 | 0.067 | [0.002; 0.319] |
| Sridhar2011Phase | 4 | 17 | 0.235 | [0.068; 0.499] |
| Worns2009Safety | 8 | 34 | 0.235 | [0.107; 0.412] |
| Escudier2009Randomized | 11 | 97 | 0.113 | [0.058; 0.194] |
| Gupta2008Phase | 5 | 30 | 0.167 | [0.056; 0.347] |
| Kloos2009Phase | 10 | 56 | 0.179 | [0.089; 0.304] |
| Lam2010Phase | 4 | 21 | 0.190 | [0.054; 0.419] |
| Maki2009Phase | 20 | 145 | 0.138 | [0.086; 0.205] |
| Matei2011Activity | 14 | 71 | 0.197 | [0.112; 0.309] |
| Miller2009Phase | 4 | 138 | 0.029 | [0.008; 0.073] |
| Moreno2009Phase | 1 | 23 | 0.043 | [0.001; 0.219] |
| Williamson2010Phase | 3 | 41 | 0.073 | [0.015; 0.199] |
| Dubey2010Phase | 13 | 50 | 0.260 | [0.146; 0.403] |
| Gitlitz2010Sorafenib | 23 | 83 | 0.277 | [0.184; 0.386] |
| Crump2010Randomized | 4 | 42 | 0.095 | [0.027; 0.226] |
| Nabors2011Phase | 5 | 47 | 0.106 | [0.035; 0.231] |
| Ott2010Phase | 2 | 35 | 0.057 | [0.007; 0.192] |
| Chen2011Response | 0 | 9 | 0.000 | [0.000; 0.336] |
| Safarinejad2010Safety | 4 | 64 | 0.062 | [0.017; 0.152] |
| Pratz2010Pharmacodynamic | 3 | 15 | 0.200 | [0.043; 0.481] |
| Amato2012Phase2 | 30 | 44 | 0.682 | [0.524; 0.814] |
| EI2012Swog | 5 | 31 | 0.161 | [0.055; 0.337] |
| Grignani2011Phase | 3 | 35 | 0.086 | [0.018; 0.231] |
| Guidetti2012Phase | 6 | 30 | 0.200 | [0.077; 0.386] |
| Man2012Sorafenib | 0 | 13 | 0.000 | [0.000; 0.247] |
| Park2012Sorafenib | 5 | 31 | 0.161 | [0.055; 0.337] |
| Ray2012Sorafenib | 6 | 39 | 0.154 | [0.059; 0.305] |
| Semrad2012Feasibility | 12 | 50 | 0.240 | [0.131; 0.382] |
| Wakelee2012Double | 54 | 333 | 0.162 | [0.124; 0.206] |
| Widemann2012Phase | 4 | 64 | 0.062 | [0.017; 0.152] |
| Kim2011Battle | 17 | 105 | 0.162 | [0.097; 0.247] |
| Chevreau2013Sorafenib | 3 | 15 | 0.200 | [0.043; 0.481] |
| Greenwald2013Phase | 5 | 14 | 0.357 | [0.128; 0.649] |
| Papa2013Phase | 8 | 53 | 0.151 | [0.067; 0.276] |
| Savvides2013Phase | 3 | 20 | 0.150 | [0.032; 0.379] |
| Yordanova2013Sorafenib | 1 | 11 | 0.091 | [0.002; 0.413] |
| Schwandt2014Randomized | 3 | 14 | 0.214 | [0.047; 0.508] |
| Random effects model | | 2517 | 0.164 | [0.138; 0.194] |

Heterogeneity: I-squared=66.1%, tau-squared=0.3342, p<0.0001

